The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group
Holly L. Geyer(Mayo Clinic Hospital), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Jean‐Jacques Kiladjian(Délégation Paris 5), Francesco Passamonti(University of Milan), Zhijian Xiao(Institute of Hematology & Blood Diseases Hospital), Gunnar Birgegård(Uppsala University Hospital), Robyn M. Scherber(Blueprint Medicines (United States)), Francisco Cervantes(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Andreas Reiter(Heidelberg University), Deepti Radia(St Thomas' Hospital), Heidi Kosiorek(Mayo Clinic in Florida), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Jan Samuelsson(Karolinska University Hospital), Björn Andréasson(NU Hospital Group), Kristina Butler(Mayo Clinic), Chiara Paoli(University of Genoa), Kari A. Martin(Mayo Clinic in Arizona), Amylou C. Dueck(Mayo Clinic in Arizona), Zhenya Senyak
Cited by 23
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k